Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
09:30am, Friday, 09'th Jan 2026
Vertex and Medtronic could see strong momentum this year, while Pfizer is still facing challenges. Regardless of what happens in 2026, though, Vertex and Medtronic have attractive prospects.
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
01:52am, Friday, 09'th Jan 2026
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32
Pfizer Turns To AI Where Drug Risk Is Highest
11:59am, Thursday, 08'th Jan 2026
Pfizer (PFE) is taking a more hands-on approach to AI in drug research, teaming up with startup Boltz to help its scientists make smarter calls earlier in the d
Pfizer Partners with Boltz to Use AI in Drug Discovery
11:53am, Thursday, 08'th Jan 2026
Pfizer Inc. (PFE, Financials) has teamed up with Boltz to add the biotech company's biomolecular AI models to its research pipeline. This will help speed up the
Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks
11:26am, Thursday, 08'th Jan 2026
Some safe dividend stocks also offer high yields. Their payouts are high but aren't risky, and are backed by strong fundamentals.
Fed Governor Wants Huge Rate Cuts This Year: 5 High-Yield Dividend Stocks to Buy Today
08:41am, Thursday, 08'th Jan 2026
Federal Reserve Governor Stephen Miran, whose term ends on January 31, argued in a recent Fox Business interview that the Fed should implement well over 100 basis points (or one percentage point) of r
Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity
08:00am, Thursday, 08'th Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity.
Cerity Partners LLC Reduces Stake in Pfizer Inc. $PFE
05:04am, Thursday, 08'th Jan 2026
Cerity Partners LLC trimmed its position in Pfizer Inc. (NYSE: PFE) by 5.3% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,738,649 shares of
Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?
03:50am, Thursday, 08'th Jan 2026
Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year.
3 Drug Stocks to Buy at a Discount
04:00pm, Wednesday, 07'th Jan 2026
Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio
02:16pm, Wednesday, 07'th Jan 2026
PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which
This Could Be Key to Pfizer's Turnaround in 2026
01:15pm, Wednesday, 07'th Jan 2026
Pfizer has been making deals in recent years to enhance its long-term growth potential. Last month, it reached a GLP-1 licensing deal with a China-based drug company.
Quant Q&A With Steven Cress
07:00am, Wednesday, 07'th Jan 2026
Steven Cress answers your questions! Credo Technology maintains A+ momentum rating, outperforming its sector across multiple timeframes despite recent stagnation concerns.
Dow Snags Another Record as Amazon Stock Leads Gains
12:23pm, Tuesday, 06'th Jan 2026
Stocks are moving higher, with the Dow Jones Industrial Average (DJI) enjoying a fresh record high
America's new vaccine doctrine for children replaces data with dogma
11:55am, Tuesday, 06'th Jan 2026
In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being
